WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today provided an update on its new commercial strategy to speed the adoption of its cardiovascular diagnostic tests -- the BGM Galectin-3(R) test and the CardioSCORETM test. <\/p>\n
Under the plan announced today, BG Medicine has begun to build its own dedicated sales organization and has taken steps to open its own CLIA lab in order to play a more active role alongside its commercial partners in driving sales and marketing efforts. In addition, the company highlighted its new Galectin-3 promotion effort, and provided an update on the regulatory and commercial path forward for CardioSCORE. <\/p>\n
\"We have taken a series of important steps over the past year to realign BG Medicine into a more commercially-focused company, capable of playing a larger role in facilitating the market adoption of our innovative cardiovascular diagnostic tests,\" said Eric Bouvier, President and CEO of BG Medicine. \"The steps outlined today represent the culmination of our efforts to transform BG Medicine. Taken together, these actions place us in a much stronger position to control our own destiny and drive our own commercial success.\" <\/p>\n
Highlights of the new commercial strategy include: <\/p>\n
In addition, the company announced a strategic reorganization in its research and development department, away from its previous focus on early stage discovery and toward a more commercially-oriented role in support of the BGM Galectin-3 and CardioSCORE tests in the marketplace. As a result of this reorganization, 11 positions in early discovery research have been eliminated, enabling the company to dedicate a greater share of its R&D budget to commercial support and market growth activities. <\/p>\n
\"The implementation of the aggressive new strategy announced today will be a critical driver in our ongoing transformation into a full-scale commercial organization,\" continued Mr. Bouvier. \"This is an important time in the evolution of BG Medicine and we look forward to sharing our progress in our execution of this strategy with our shareholders.\" <\/p>\n
About BG Medicine, Inc. <\/p>\n
BG Medicine, Inc. (BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company's first commercialized product, the BGM Galectin-3(R) test for use in patients with chronic heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORETM test, a blood test designed to aid in the assessment of an individual's risk for near-term major cardiovascular events. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http:\/\/www.bg-medicine.com<\/a> and http:\/\/www.galectin-3.com<\/a>. <\/p>\n The BG Medicine Inc. logo is available at http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352<\/a> <\/p>\n Special Note Regarding Forward-looking Statements <\/p>\n<\/p>\n See the original post here:<\/p>\n BG Medicine Outlines New Commercial Strategy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" WALTHAM, Mass., Nov. Continue reading